An In Vivo Metastasis Model Using Genotype-Defined Tumor Organoids.

Methods Mol Biol

Division of Genetics, Cancer Research Institute, Kanazawa University, Kanazawa, Japan.

Published: August 2024


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Recent cancer genome analyses have identified frequently mutated genes that are responsible for the development and malignant progression of cancers, including colorectal cancer (CRC). We previously constructed mouse models that carried major driver mutations of CRC, namely Apc, Kras, Tgfbr2, Trp53, and Fbxw7, in combinations. Comprehensive histological analyses of the models showed a link between mutation combinations and malignant phenotypes, such as invasion, epithelial-mesenchymal transition (EMT), and metastasis. The major cause of cancer-related death is metastasis, making it important to understand the mechanism underlying metastasis in order to develop novel therapeutic strategies. To this end, we have established intestinal tumor-derived organoids from different genotyped mice and generated liver metastasis models via transplantation of the organoids into the spleen. Through histological and imaging analyses of the transplantation models, we have determined that the combination of Apc, Kras, Tgfbr2, and Trp53 mutations promotes liver metastasis at a high incidence. We also demonstrated polyclonal metastasis of tumor cell clusters consisting of genetically and phenotypically distinct cells through our model analysis. These organoid transplantation models recapitulate human CRC metastasis, constituting a useful tool for basic and clinical cancer research as a preclinical model. We herein report the experimental protocols of the organoid culture and generation of metastasis models.

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-1-0716-4023-4_6DOI Listing

Publication Analysis

Top Keywords

apc kras
8
kras tgfbr2
8
tgfbr2 trp53
8
metastasis
8
liver metastasis
8
metastasis models
8
transplantation models
8
models
6
vivo metastasis
4
metastasis model
4

Similar Publications

UBE2C promotes pancreatic tumorigenesis by KRAS stabilization via APC/C-mediated WDR76 degradation.

Cancer Lett

August 2025

Department of Hepatobiliary and Pancreatic Surgery, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China; Zhejiang Provincial Key Laboratory of Pancreatic Disease, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China; Institute of T

Bioinformatics-based association study revealed a strong positive correlation between UBE2C, an E2 ubiquitin-conjugating enzyme, and pancreatic cancer and patient survival. However, whether and how UBE2C plays a causal role in pancreatic tumorigenesis remains elusive. Here, we report that UBE2C functions as a promoter in this process.

View Article and Find Full Text PDF

Results of a French screening campaign comparing clinical and molecular characteristics of interval colorectal cancers to cancers detected using a guaiac test.

Clin Res Hepatol Gastroenterol

September 2025

Service d'Hépato-Gastroentérologie, CHU Angers, 4 rue Larrey, 49933Angers Cedex 09, France. Electronic address:

Few studies have analyzed the biological characteristics of interval colorectal cancers (CRC) during a screening campaign. We included 98 patients of whom 46 had a screened cancer (SCG) and 52 an interval cancer (ICG). Microsatellite instability and gene mutation profiling were performed in 86 and 55 patients, respectively.

View Article and Find Full Text PDF

Purpose: Colorectal liver metastases (CRLM) pose a significant clinical challenge due to their high recurrence rates, even after surgical resection. There is an urgent need for reliable prognostic biomarkers to improve risk stratification and guide treatment decisions for CRLM patients.

Methods/patients: In this study, we performed whole-exome sequencing (WES) on 57 CRLM patients and conducted a comparative genomic analysis of primary tumors and matched liver metastases in 8 patients.

View Article and Find Full Text PDF

With the introduction of early-onset colorectal cancer (EO-CRC), defined as diagnosis before the age of 50, research has increasingly focused on distinguishing it from late-onset colorectal cancer (LO-CRC). However, the majority of these studies have delved deeply into specific aspects of the condition, and there is still a limited number of articles that comprehensively review the overall differences between EO-CRC and LO-CRC. In this review, we conducted literature searches on PubMed, Embase, and ScienceDirect databases using keywords such as "early-onset colorectal cancer", and "late-onset colorectal cancer".

View Article and Find Full Text PDF

The incidence of -naïve gastric neoplasms (HpNGNs) is increasing due to a growing -naïve population and improved recognition. Among these, HpNGNs that predominantly exhibit foveolar-cell differentiation include foveolar-type gastric adenomas (FGA) and fundic gland polyps with dysplasia (FGPD). Traditionally, FGAs have been considered large, whitish, flat lesions (flat-type FGA), primarily associated with syndromic conditions, such as familial adenomatous polyposis (FAP) and gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS), while sporadic cases are rare.

View Article and Find Full Text PDF